Specify a stock or a cryptocurrency in the search bar to get a summary
Xeris Pharmaceuticals Inc
2B30Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 180 North LaSalle Street, Chicago, IL, United States, 60601
Analytics
WallStreet Target Price
4.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2B30
Dividend Analytics 2B30
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2B30
Stock Valuation 2B30
Financials 2B30
Results | 2019 | Dynamics |